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INTRODUCTION:                    
The 5-HT neurotransmission system is targeted by drugs 
useful in behavioural disorders, including anxiety, 
depression, psychosis and eating disorders. 
5-HT1A autoreceptors, located on 5-HT neurones of the 
midbrain raphe nuclei, are coupled to K channels through 
a pertusis toxin-sensitive G-protein1. Their activation 
hyperpolarizes 5-HT neurones and inhibits their firing 
activity2. 5-HT1A receptors are localised 
postsynaptically to 5-HT terminals, mainly in limbic and 
cortical structures3. The activation of postsynaptic 5-
HT1A receptors in cortical and hippocampus pyramidal 
neurones is also associated with hyperpolarization and 
reduction of their firing activity4, mediate the inhibition 
of forkolin-stimulated adenylyl cyclase activity; using 
the method of partial irreversible receptor activation5. 
5-HT1A receptor agonists exhibit anxiolytic and/or 
antidepressant activity in experimental models, and some 
members of the azapirone family, e.g., buspirone and 
gepirone, are used in the treatment of affective 
disorders6,7. These drugs are also found to decrease 
feeding in food-deprived animals8.     
In anxiety disorders, changes in the corticosteroid 
concentration and serotonergic transmission are 
observed, on which 5-HT1A receptor agonists are 
clinically effective9, via the activation of glucocoticoid 
receptors by corticosterone, stressful stimuli enhance the 
activity of tryptophan hydroxylase and increase brain 5-
HT turnover and extracellular 5-HT levels10. Reduction 
of 5-HT neurotransmission is thought to have an 
anxiolytic effect. The role of presynaptic 5-HT1A 
receptors located in the raphe nuclei in mediating the 
anxiolytic effects of 5-HT1A agonists has been 
demonstrated in animal models11. It has been suggested 
that the anxiolytic effect of 5-HT1A receptor agonists 
require action in the dorsal raphe nucleus through the 
stimulation of somatodendritic 5-HT1A autoreceptors, 
resulting in less firing of serotonergic neurones and a 
subsequent reduction in 5-HT release12. Moreover, the 
glucocorticoid receptor antagonists like RU 38486 were 
shown to display anxiolytic-like activity in rats13. Thus, it 
can be hypothesised that the decreased density of 
glucocorticoid receptor binding sites in the raphe nuclei 
following 5-HT1A receptor activation contributes to the 
anxiolytic action of 5-HT1A agonists by restoring the 
efficiency of 5-HT1A autoreceptor in the negative 
control of the electrical activity of serotonergic 
neurones14. The regulation of 5-HT1A receptor is of 
considerable clinical importance as its adaptive changes 
appear to play an important role in the therapeutic effect 
of antidepressants. 
The stimulation of 5-HT1A receptor attenuates the 
extrapyramidal side effects of antipsychotic. For 
example, 5-HT1A receptor agonists attenuate 
antipsychotic-induced extrapyramidal side effects in 
human15 and non-human primates16, and antipsychotic-
induced catalepsy in rats17. The increased interest in 5-
HT1A receptors in antipsychotic research is evidenced 
by reports of novel antidopaminergic compound with 
affinity at 5-HT1A receptors18.   
5-HT1A receptor may have a beneficial effect for 
treatment of schizophrenia, since the activation of 
postsynsptic 5-HT1A receptors results in the activation 
of cortical dopaminergic system which may be important 
for ameliorating effect of atypical antipsychotic drugs on 
negative symptoms in schizophrenia19, 20. Also it is 
known that 5-HT1A receptors can induce the deficits 
passive avoidance retention, not 5-HT2A receptors21. 
 5-HT1A agonists induce multiple behavioural effects, 
e.g. modulate both general locomotor activity22, 
nonciceptive thresholds23 and elicit a characteristic 
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behavioural syndrome (5-HT syndrome) 24. These factors 
may interfere with learning performance by alteration of 
sensory input at the initial stage of information 
processing25. 
 The stimulation of presynaptic 5-HT1A receptor is 
involved in the ability of 8-OH-DPAT, a 5-HT1A 
receptor agonist, to cause attentional dysfunction and 
enhance impulsivity while slowing of responding and 
increase in errors of omission mainly depend on 
stimulation of postsynaptic 5-HT1A receptors26.  
The 5-HT is a major inhibitory agent of glutamatergic 
transmission in the human cerebral cortex. Not only 
serotonin inhibits the evoked release of glutamate from 
nerve terminals by acting at presynaptic 5-HT1D 
receptors, it also can inhibit events triggered by 
glutamate release by acting at presynaptic receptors of 
the 5-HT1A and of the 5-HT2C subtype. Whatever the 
mechanisms, agonists at human 5-HT1D, 5-HT2C and 5-
HT1A receptors may be the potentially useful drugs in 
neuropathologies with underlying excessive 
glutamatergic transmission27. 
The human 5-HT2A and 5-HT2C receptor agonists 
differentially activate two signal transduction pathways 
independently coupled to these receptors28 
(Phospholipase C-mediated inositol phosphate 
accumulation and Phospholipase A2-mediated 
arachidonic acid release). The transcript encoding the 5-
HT2C receptor undergo RNA editing events in which 
genomically encoded adenosine residues are converted to 
inosines by the action of double-stranded RNA 
deaminase29. It has been suggested that this may affect 
receptor G-protein coupling efficiency, and hence the 
potency and efficacy of agonists may vary depending on 
the being studied. 
Newton et al30 (1998) expressed human 5-HT2A and 5-
HT2C receptors in SHSY5Y cells. Both studies found 5-
HT to be more potent at 5-HT2C receptor than 5-HT2A 
receptor. 
Recently it is found that the selective 5-HT2C receptor 
agonist Ro60-0175 can mimic many of the specific 
effects of the prototypical anorectic drug d-fenfluramine 
on feeding behaviour. In addition, the selective 5-HT2C 
receptor antagonist SB 242084 either completely blocks, 
or, substantially attenuates the behavioural effects on 
feeding of both d-fenfluramine and Ro60-0175 with the 
exception of meal size31. These results strongly support 
the investigation of 5-HT2C receptor agonists as 
clinically effective anorectic drugs that avoid the 
peripheral cardiovascular side effects that may be 
associated with indirect agonist such as d-fenfluramine
32
. 
Orexin-A-induced grooming is primary mediated by 
OX1 receptors with involvement of downstream 5-HT2C 
receptors. This study also suggested that orexin-A does 
not indirectly activate 5-HT2C receptors throughout the 
rat CNS, but instead activates a neuroanatomically 
discrete population of 5-HT2C receptors to increase rat 
grooming. In preliminary findings by Brown and Haas34 
(2000) demonstrated that orexin-A increases firing of 
neurones in the dorsal raphe nucleus. This suggests that 
antagonism of 5-HT2C receptors can useful in anxiety 
and anxiety related disorders.  
Lithium effectively controls manic-depressive illness35. 
A possible explanation is that lithium modifies a 
downstream pathway to re-establish normal responses to 
the 5-HT2C receptor, which is proposed to be one of the 
receptor responsible for manic-depressive illness, 
perhaps by interaction with phosphoinsitide metabolic 
pathway. Lithium inhibits inositol signalling mainly by 
its specific effect on the 5-HT2C receptor and acts as an 
inhibitor of inositol phosphate metabolism36. 
Like the 5-HT1A receptor agonism, the 5-HT2C receptor 
antagonism also decreases the extrapyramidal side 
effects of ‘atypical’ antipsychotic drugs37.    
CONCLUSION: 
The 5-HT1A receptor agonists inhibit adenylyl cyclase, 
while 5-HT2C receptor agonists activate two signal 
transduction pathways coupled with these receptors. The 
above findings suggests that selective subtype drugs of 
5-HT1A and 5-HT2C receptors have lots potential in 
treating the disorders with less or no side effects. 
The 5-HT1A receptors are potential target for anxiety, 
depression, eating disorders and for extrapyramidal side 
effects of atypical antipsychotics, the 5-HT2C receptors 
for anxiety /panic, anxiety related disorders like OCD, 
maniac-depressive illness. 
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